Am Heart J

1. HAMO CE, Mukhopadhyay A, Li X, Zheng Y, et al
   Association between Visit Frequency, Continuity of Care, and Pharmacy Fill Adherence in Heart Failure Patients.
   Am Heart J. 2024 Apr 13:S0002-8703(24)00090-5. doi: 10.1016/j.ahj.2024.
   

   >> Share

   
   

   
   Am J Cardiol

2. ARIAS-MENDOZA A, Gopar-Nieto R, Juarez-Tolen J, Ordonez-Olvera JC, et al
   Long Term Outcomes of Pharmacoinvasive Strategy vs. Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction: A Study From Mexico City.
   Am J Cardiol. 2024 Feb 23:S0002-9149(24)00113.
   

   >> Share

   
   
3. SINGH S, Garg A, Tantry US, Bliden K, et al
   Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes.
   Am J Cardiol. 2024 Mar 1:S0002-9149(24)00161.
   

   >> Share

   
   
4. AHMED SI, Kenyon J, Billingsley HE, Salmons H, et al
   Corrigendum to 'Objectively Measured Night-Time Sleep Efficiency and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction' [American Journal of Cardiology 208 (2023) 124-125].
   Am J Cardiol. 2024 Apr 13:S0002-9149(24)00259.
   

   >> Share

   
   

   
   BMJ

5. VINTER N, Cordsen P, Johnsen SP, Staerk L, et al
   Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study.
   BMJ. 2024;385:e077209.
   

   >> Share

   
   
6. MOK PLH, Carr MJ, Guthrie B, Morales DR, et al
   Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.
   BMJ. 2024;385:e076268.
   

   >> Share

   
   

   
   Cardiol Clin

7. SHEEHAN M, Sokoloff L, Reza N
   Acute Heart Failure: From The Emergency Department to the Intensive Care Unit.
   Cardiol Clin. 2024;42:165-186.
   

   >> Share

   
   
8. KEANE RR, Menon V, Cremer PC
   Acute Heart Valve Emergencies.
   Cardiol Clin. 2024;42:237-252.
   

   >> Share

   
   
9. BHATTACHARYA S
   Emergencies in Pulmonary Hypertension.
   Cardiol Clin. 2024;42:273-278.
   

   >> Share

   
   

   
   Circ Cardiovasc Interv

10. GRAYBURN PA, Mack MJ, Manandhar P, Kosinski AS, et al
    Comparison of Transcatheter Edge-to-Edge Mitral Valve Repair for Primary Mitral Regurgitation Outcomes to Hospital Volumes of Surgical Mitral Valve Repair.
    Circ Cardiovasc Interv. 2024 Mar 4:e013581.
    

    >> Share

    
    

    
    Circ Cardiovasc Qual Outcomes

11. WADHERA RK, Secemsky EA, Xu J, Yeh RW, et al
    Community Socioeconomic Status, Acute Cardiovascular Hospitalizations, and Mortality in Medicare, 2003 to 2019.
    Circ Cardiovasc Qual Outcomes. 2024 Apr 10:e010090.
    

    >> Share

    
    

    
    Circ Genom Precis Med

12. DE FRUTOS F, Diez-Lopez C, Garcia-Romero E, Gondra L, et al
    Dilated Cardiomyopathy With Concomitant Salt-Losing Renal Tubulopathy Caused by Heterozygous RRAGD Gene Variant.
    Circ Genom Precis Med. 2024;17:e004336.
    

    >> Share

    
    

    
    Circ Heart Fail

13. SHAH P, Agbor-Enoh S, Lee S, Andargie TE, et al
    Racial Differences in Donor-Derived Cell-Free DNA and Mitochondrial DNA After Heart Transplantation, on Behalf of the GRAfT Investigators.
    Circ Heart Fail. 2024 Feb 20:e011160. doi: 10.1161/CIRCHEARTFAILURE.123.011160.
    

    >> Share

    
    
14. CELUTKIENE J, Cerlinskaite-Bajore K, Cotter G, Edwards C, et al
    Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial.
    Circ Heart Fail. 2024;17:e011221.
    

    >> Share

    
    
15. BRYSON TD, Bhat SY, Moore C, Taube D, et al
    Targeted Gene Deletion or Antagonism of the Prostaglandin E2 EP3 Receptor Protects Against Cardiac Injury Postmyocardial Infarction.
    Circ Heart Fail. 2024;17:e011089.
    

    >> Share

    
    
16. DAGAN M, Kaye DM
    Making Waves in HFpEF: Unmasking Severe Left Atrial Myopathy During Exercise.
    Circ Heart Fail. 2024;17:e011237.
    

    >> Share

    
    
17. WU W, Jin Q, Ostlund C, Tanji K, et al
    mTOR Inhibition Prolongs Survival and Has Beneficial Effects on Heart Function After Onset of Lamin A/C Gene Mutation Cardiomyopathy in Mice.
    Circ Heart Fail. 2024;17:e011110.
    

    >> Share

    
    
18. KANAOKA K, Onoue K, Terasaki S, Nakai M, et al
    Changes in Cardiac Function Following Fulminant Myocarditis.
    Circ Heart Fail. 2024;17:e010840.
    

    >> Share

    
    
19. KAPUR NK, Reyelt L, Everett K, Mahmoudi E, et al
    Mechanically Regulating Cardiac Preload to Maximize Left Ventricular Unloading With a Transvalvular Microaxial Flow Pump.
    Circ Heart Fail. 2024;17:e011330.
    

    >> Share

    
    
20. AGARWAL A, Tromp J, Almahmeed W, Angermann C, et al
    Toward a Universal Definition of Etiologies in Heart Failure: Categorizing Causes and Advancing Registry Science.
    Circ Heart Fail. 2024;17:e011095.
    

    >> Share

    
    
21. ALMUFLEH A, Givertz MM
    Is My Patient Fit for Surgery? Navigating Between the Rock of Heart Failure and the Hard Place of Semiurgent Surgery.
    Circ Heart Fail. 2024 Apr 19:e011609. doi: 10.1161/CIRCHEARTFAILURE.124.011609.
    

    >> Share

    
    

    
    Circ Res

22. QASIM H, Rajaei M, Xu Y, Reyes-Alcaraz A, et al
    AKAP12 Upregulation Associates With PDE8A to Accelerate Cardiac Dysfunction.
    Circ Res. 2024;134:1006-1022.
    

    >> Share

    
    

    
    Circulation

23. 
    Correction to: Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure.
    Circulation. 2024;149:e1130.
    

    >> Share

    
    
24. LI B, Liu F, Chen X, Chen T, et al
    FARS2 Deficiency Causes Cardiomyopathy by Disrupting Mitochondrial Homeostasis and the Mitochondrial Quality Control System.
    Circulation. 2024;149:1268-1284.
    

    >> Share

    
    

    
    Clin Cardiol

25. ITO R, Kondo Y, Nakano M, Kajiyama T, et al
    Interaction of left ventricular size with the outcome of cardiac resynchronization therapy in Japanese patients.
    Clin Cardiol. 2024;47:e24267.
    

    >> Share

    
    

    
    Eur Heart J

26. WYLD M, Webster AC
    Myocardial infarction and stroke in patients with kidney failure: can we do better?
    Eur Heart J. 2024 Mar 27:ehae153. doi: 10.1093.
    

    >> Share

    
    

    
    Eur J Heart Fail

27. OEXNER RR, Ahn H, Theofilatos K, Shah RA, et al
    Serum metabolomics improves risk stratification for incident heart failure.
    Eur J Heart Fail. 2024 Apr 16. doi: 10.1002/ejhf.3226.
    

    >> Share

    
    
28. PORCARI A, Fontana M
    The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: Is the time ripe for clinical use of sodium-glucose cotransporter 2 inhibitors?
    Eur J Heart Fail. 2024 Apr 16. doi: 10.1002/ejhf.3245.
    

    >> Share

    
    
29. JALLOH MB, Bot VA, Borjaille CZ, Thabane L, et al
    Reporting quality of heart failure randomized controlled trials 2000-2020: Temporal trends in adherence to CONSORT criteria.
    Eur J Heart Fail. 2024 Apr 16. doi: 10.1002/ejhf.3229.
    

    >> Share

    
    
30. DHONT S, van den Acker G, van Loon T, Verbrugge FH, et al
    Mitral regurgitation in heart failure with preserved ejection fraction: The interplay of valve, ventricle, and atrium.
    Eur J Heart Fail. 2024 Apr 17. doi: 10.1002/ejhf.3231.
    

    >> Share

    
    
31. AMERI P, Mercurio V, Pollesello P, Anker MS, et al
    A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function.
    Eur J Heart Fail. 2024 Apr 19. doi: 10.1002/ejhf.3236.
    

    >> Share

    
    

    
    Heart

32. CUTHBERT JJ, Soyiri I, Lomax SJ, Turgoose J, et al
    Outcomes in patients treated with loop diuretics without a diagnosis of heart failure: a retrospective cohort study.
    Heart. 2024 Apr 17:heartjnl-2023-323577. doi: 10.1136/heartjnl-2023-323577.
    

    >> Share

    
    
33. MERCADE-BESORA N, Li X, Kolde R, Trinh NT, et al
    The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications.
    Heart. 2024 Mar 12:heartjnl-2023-323483. doi: 10.1136/heartjnl-2023-323483.
    

    >> Share

    
    

    
    Hypertension

34. HU Y, Lin L, Zhang L, Li Y, et al
    Identification of Circulating Plasma Proteins as a Mediator of Hypertension-Driven Cardiac Remodeling: A Mediation Mendelian Randomization Study.
    Hypertension. 2024 Mar 15. doi: 10.1161/HYPERTENSIONAHA.123.22504.
    

    >> Share

    
    
35. YU J, Arnott C, Li Q, Di Tanna GL, et al
    Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes.
    Hypertension. 2024 Mar 11. doi: 10.1161/HYPERTENSIONAHA.123.22410.
    

    >> Share

    
    
36. CAMARDA ND, Ibarrola J, Biwer LA, Jaffe IZ, et al
    Mineralocorticoid Receptors in Vascular Smooth Muscle: Blood Pressure and Beyond.
    Hypertension. 2024;81:1008-1020.
    

    >> Share

    
    

    
    Int J Cardiol

37. JONG CB, Lu TS, Chen JW
    Reply to comment on "Subclinical myocardial injury increases the risk of heart failure in patients with and without type 2 diabetes post-acute coronary syndrome".
    Int J Cardiol. 2024 Apr 10:132031. doi: 10.1016/j.ijcard.2024.132031.
    

    >> Share

    
    

    
    J Am Coll Cardiol

38. KITTIPIBUL V, Cox ZL, Chesdachai S, Fiuzat M, et al
    Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2024;83:1568-1578.
    

    >> Share

    
    

    
    J Card Fail

39. DUAL SA, Cowger J, Roche E, Nayak A, et al
    The Future of Durable Mechanical Circulatory Support: Emerging Technological Innovations and Considerations to Enable Evolution of the Field.
    J Card Fail. 2024;30:596-609.
    

    >> Share

    
    
40. ROSSELLO X
    Safety Indicators in the STRONG-HF Trial From a Methodological Perspective.
    J Card Fail. 2024;30:538-540.
    

    >> Share

    
    
41. ALVIAR CL, Hall S, Mebazaa A
    Outcomes of Patients With Cardiogenic Shock in Hub and Spoke Centers: The importance of Protocol Standardization at a Network Level.
    J Card Fail. 2024;30:576-579.
    

    >> Share

    
    
42. DRIGGIN E, Goyal P
    Malnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF.
    J Card Fail. 2024;30:610-612.
    

    >> Share

    
    
43. BRANN A, Kim IC
    Labels of Strategic Intent for LVAD Implantation: "What's in a Name?".
    J Card Fail. 2024;30:562-563.
    

    >> Share

    
    
44. SPERRY BW, Zein RE, Fendler TJ, Sauer AJ, et al
    Stabilization of Rapidly Progressive Cardiac Allograft Vasculopathy Using mTOR Inhibition After Heart Transplantation.
    J Card Fail. 2024;30:613-617.
    

    >> Share

    
    
45. RALI AS, Inampudi C, Zalawadiya S, Shah A, et al
    Changing Strategy Between Bridge to Transplant and Destination LVAD Therapy After the First 3 Months: Analysis of the STS-INTERMACS Database.
    J Card Fail. 2024;30:552-561.
    

    >> Share

    
    
46. GARAN AR, Kataria R, Li B, Sinha S, et al
    Outcomes of Patients Transferred to Tertiary Care Centers for Treatment of Cardiogenic Shock: A Cardiogenic Shock Working Group Analysis.
    J Card Fail. 2024;30:564-575.
    

    >> Share

    
    
47. BUTLER J, Nair A, Shahzeb Khan M
    Body Mass Index Distribution Among Patients with Heart Failure and Reduced Ejection Fraction: Implication for Future Trials.
    J Card Fail. 2024 Apr 17:S1071-9164(24)00117.
    

    >> Share

    
    
48. SHAH A, Rao VN
    Troponin in Heart Failure: Innocent Bystander or Harbinger of Risk?
    J Card Fail. 2024 Apr 12:S1071-9164(24)00122.
    

    >> Share

    
    
49. 
    President's Page in JCF: HFSA and the World.
    J Card Fail. 2024;30:635-636.
    

    >> Share

    
    
50. FANG JC, Wilson BH, Wu JC, Hurwitz JL, et al
    Modernizing Cardiovascular Medicine Board Certification: Leveraging Innovation and Strengthening Continuous Competency and Professional Growth.
    J Card Fail. 2024;30:633-634.
    

    >> Share

    
    

    
    J Cardiol

51. BUTTER L, Haase-Fielitz A, Zanker M, Becher G, et al
    Cluster analysis of volatile organic compounds - a pilot study in patients with severe acute decompensated heart failure.
    J Cardiol. 2024 Apr 13:S0914-5087(24)00062-5. doi: 10.1016/j.jjcc.2024.
    

    >> Share

    
    
52. SHIINA Y, Nagao M, Itatani K, Shimada E, et al
    4D flow MRI-derived energy loss and RV workload in adults with tetralogy of Fallot.
    J Cardiol. 2024;83:382-389.
    

    >> Share

    
    

    
    J Thorac Cardiovasc Surg

53. SIMPSON MT, Ning Y, Kurlansky P, Colombo PC, et al
    Outcomes of treatment for deep left ventricular assist device infection.
    J Thorac Cardiovasc Surg. 2024;167:1824-1832.
    

    >> Share

    
    
54. SILVESTRY SC
    Commentary: Tricuspid repair and left ventricular assist device: A new baseline.
    J Thorac Cardiovasc Surg. 2024;167:1821-1822.
    

    >> Share

    
    
55. MENDIOLA PLA M, Chiang Y, Nicoara A, Poehlein E, et al
    Surgical Treatment of Tricuspid Valve Regurgitation in Patients Undergoing Left Ventricular Assist Device Implantation: Interim analysis of the TVVAD trial.
    J Thorac Cardiovasc Surg. 2022 Nov 16:S0022-5223(22)01243.
    

    >> Share

    
    
56. PAGANI FD
    Commentary: Lack of benefit of tricuspid valve intervention with left ventricular assist device implantation? It's all in the details.
    J Thorac Cardiovasc Surg. 2023 Jan 21:S0022-5223(23)00084.
    

    >> Share

    
    
57. KONSTANTINOV IE, Davies B
    Durable ventricular assist device implantation in a child after double switch operation.
    J Thorac Cardiovasc Surg. 2024;167:1566-1569.
    

    >> Share

    
    
58. GREENBERG JW, Kulshrestha K, Guzman-Gomez A, Fields K, et al
    Modifiable risk factor reduction for pediatric ventricular assist devices and the influence of persistent modifiable risk factors at transplant.
    J Thorac Cardiovasc Surg. 2024;167:1556-1563.
    

    >> Share

    
    
59. 
    Discussion to: Modifiable risk factor reduction for pediatric ventricular assist devices and the influence of persistent modifiable risk factors at transplant.
    J Thorac Cardiovasc Surg. 2024;167:1564-1565.
    

    >> Share

    
    

    
    N Engl J Med

60. YNDIGEGN T, Lindahl B, Mars K, Alfredsson J, et al
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2401479.
    

    >> Share

    
    

    
    PLoS One

61. HUTTELMAIER MT, Munsterer S, Morbach C, Sahiti F, et al
    Activated rate-response is associated with increased mortality risk in cardiac device carriers with acute heart failure.
    PLoS One. 2024;19:e0302321.
    

    >> Share

    
    
62. SAIFAN AR, Hayeah HA, Ibrahim AM, Dimitri A, et al
    Experiences on health-related quality of life of Jordanian patients living with heart failure: A qualitative study.
    PLoS One. 2024;19:e0298893.
    

    >> Share

    
    
63. ZHANG X, Ho GWK, Mak YW
    Effectiveness of a videoconferencing group-based dyad acceptance and commitment therapy on the quality of life of chronic heart failure patients and their family caregivers: A study protocol for a randomized controlled trial.
    PLoS One. 2024;19:e0298178.
    

    >> Share

    
    
64. RYE CS, Ofstad AP, Asvold BO, Romundstad PR, et al
    The influence of diagnostic subgroups, patient- and hospital characteristics for the validity of cardiovascular diagnoses-Data from a Norwegian hospital trust.
    PLoS One. 2024;19:e0302181.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share